Minocycline and Tobacco Craving in Smokers With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Catonsville, Maryland, United States, 21228
- Maryland Psyciatric Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- DSM-IV or DSM-5 diagnosis of schizophrenia or schizoaffective disorder
- Male or Female
- Age: 18 to 65 years
- Caucasian or Non-Caucasian
- Smoke at least 10 cigarettes daily
- Urine cotinine level ≥ 100 ng/ml (NicAlert® reading ≥ 3)
- Agrees to wear a head mounted display (HMD) for up to 45 minutes
- Able to complete the Evaluation to Sign Consent (ESC) with minimum score of 80%
Exclusion Criteria
- History of organic brain disease
- DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
- DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
- Pregnancy or lactation
- Severe liver dysfunction (LFT 3X upper limit of normal)
- Previous known hypersensitivity to tetracyclines
- Current treatment with tetracycline or derivative
- Treatment with oral contraceptives (unless a second form of birth control is used and documented)
- Treatment with cholestyramine or colestipol
- Treatment with Urinary alkalinizers (e.g., sodium lactate, potassium citrate)
- Treatment with warfarin
- Treatment with bupropion, varenicline, or nicotine replacement products in the month prior to study inclusion
- Less than two months treatment of adjunctive medications AND less than one month on same dose: beta blockers, antidepressants, mood stabilizers, antianxiety medications.
- Medical condition whose pathology or treatment would significantly increase the risk associated with the proposed protocol.
- History of head injury, seizures, or stroke
- Positive urine toxicology screen for substances of non-therapeutic use prior to craving assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Minocycline
Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
|
Minocycline capsules taken twice daily for two weeks.
|
|
Placebo Comparator: Placebo
Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
|
Placebo capsules taken twice daily for two weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire for Smoking Urges-Brief
Time Frame: Baseline, Week 1, and Week 2
|
This is a 10-item assessment used to measure craving to smoke and used in studies of smokers with schizophrenia.
This scale has a score range from 0-100The change in QSU-Brief craving scores between time points (baseline to week 1, and baseline to week 2) will be assessed.
The change in scores between the two timepoints will be calculated.
The higher the score the stronger the urge to smoke is.
|
Baseline, Week 1, and Week 2
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HP-00072110
- 4K23DA034034-04 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.